SCHEMBL19782373

SCHEMBL19782373

COc1ccc(-c2cc(-c3ccc(Cl)cc3)nc(=O)[nH]2)cc1OC

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL12 P48061 2/20 0.72
KDM4E B2RXH2 4/20 0.55
MAPT P10636 3/20 0.50
THRB P10828 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.49
PDGFRB P09619 1/20 0.47
TP53 P04637 1/20 0.46
CDC7 O00311 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
ALOX5 P09917 1/20 0.45
TSHR P16473 1/20 0.44
RAB9A P51151 1/20 0.44
MCHR1 Q99705 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19783001 0.90 CXCL12 (0.65) CXCL12KDM4EMAPTTHRBMEN1
SCHEMBL19782686 0.89 CXCL12 (0.91) CXCL12KDM4EMEN1KMT2AALDH1A1
SCHEMBL19782797 0.89 CXCL12 (0.74) CXCL12KDM4EMAPTMEN1KMT2A
SCHEMBL23549450 0.89 CXCL12 (0.61) CXCL12KDM4EMAPTTHRBMEN1
SCHEMBL22065544 0.89 CXCL12 (0.64) CXCL12KDM4EMAPTTHRBMEN1
SCHEMBL22065023 0.89 CXCL12 (0.64) CXCL12KDM4EMAPTTHRBMEN1
SCHEMBL23549449 0.88 CXCL12 (0.63) CXCL12KDM4EMAPTTHRBMEN1
SCHEMBL19782806 0.87 CXCL12 (0.76) CXCL12KDM4EMAPTMEN1KMT2A
SCHEMBL19782997 0.87 CXCL12 (0.62) CXCL12KDM4EMAPTTHRBMEN1
SCHEMBL19783037 0.86 CXCL12 (0.67) CXCL12KDM4EMAPTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046657-B2 Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-06-29 US disclosed
US-20200181093-A1 Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2020-06-11 US disclosed
WO-2018011376-A1 PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200181093-A1 Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines CCL5, CXCR3, CXCL10 CXCL12 18/4885KDM4E 4286/4885MAPT 1279/4885
US-11046657-B2 Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines CCL5, CXCR3, CXCL10 CXCL12 18/4885KDM4E 4286/4885MAPT 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.